Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

Amneal received FDA approval for additional strengths and vial presentations of iohexol injection, including 350 mg iodine/mL and 300 mg iodine/mL in various sizes, significantly expanding its injectable contrast portfolio. These approvals represent the first generic versions referencing GE HealthCare's OMNIPAQUE across the approved presentations and position the company to address the majority of the approximately $706 million U.S. market demand.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.